Compounds > angiotensin ii
Page last updated: 2024-08-22

angiotensin ii and ema400

angiotensin ii has been researched along with ema400 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Rice, AS; Smith, MT1
Anand, P; Anand, U; Bountra, C; Fox, M; Korchev, YE; MacQuillan, A; McCarthy, T; Quick, T; Sinisi, M; Yiangou, Y1
Chatziathanasiadou, MV; Cherezov, V; Choi, JJ; Crook, T; El Mubarak, MA; Han, GW; Kanaki, Z; Katritch, V; Klinakis, A; Kostagianni, AD; Lattanzio, L; Lebon, G; Lo Nigro, C; Morse, SV; O'Neill, K; Perryman, R; Renziehausen, A; Shaye, H; Sivolapenko, GB; Syed, N; Thorne, T; Tsiailanis, AD; Tzakos, AG; Zarzycka, B1

Other Studies

3 other study(ies) available for angiotensin ii and ema400

ArticleYear
Angiotensin II type 2-receptor: new clinically validated target in the treatment of neuropathic pain.
    Clinical pharmacology and therapeutics, 2015, Volume: 97, Issue:2

    Topics: Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Benzhydryl Compounds; Disease Models, Animal; Humans; Isoquinolines; Models, Neurological; Molecular Targeted Therapy; Neuralgia; Receptor, Angiotensin, Type 2; Reproducibility of Results

2015
Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies.
    Molecular pain, 2015, Jun-26, Volume: 11

    Topics: Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Benzhydryl Compounds; Calcium; Female; Ganglia, Spinal; Humans; Immunohistochemistry; Isoquinolines; Mitogen-Activated Protein Kinase 3; Models, Biological; Nerve Tissue; Neuralgia; Neurites; p38 Mitogen-Activated Protein Kinases; Rats, Wistar; Receptor, Angiotensin, Type 2; Signal Transduction; TRPV Cation Channels

2015
Inhibition of the angiotensin II type 2 receptor AT
    Proceedings of the National Academy of Sciences of the United States of America, 2022, 08-09, Volume: 119, Issue:32

    Topics: Analgesics; Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Apoptosis; Benzhydryl Compounds; Brain Neoplasms; Drug Repositioning; Glioblastoma; Humans; Isoquinolines; Protein Conformation, alpha-Helical; Receptor, Angiotensin, Type 2; Tumor Burden

2022